Clinical Trial Update: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [Phase 3]

View source ↗

Summary

Phase 3 update reporting cardiovascular outcomes results from Amgen's PCSK9 inhibitor program in individuals at elevated risk with dyslipidemia. The study exami…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2018-02-15